PMID- 11489918 OWN - NLM STAT- MEDLINE DCOM- 20010906 LR - 20211203 IS - 0021-9525 (Print) IS - 1540-8140 (Electronic) IS - 0021-9525 (Linking) VI - 154 IP - 3 DP - 2001 Aug 6 TI - Neuronal survival induced by neurotrophins requires calmodulin. PG - 585-97 AB - It has been reported that phosphoinositide 3-kinase (PI 3-kinase) and its downstream target, protein kinase B (PKB), play a central role in the signaling of cell survival triggered by neurotrophins (NTs). In this report, we have analyzed the involvement of Ca2+ and calmodulin (CaM) in the activation of the PKB induced by NTs. We have found that reduction of intracellular Ca2+ concentration or functional blockade of CaM abolished NGF-induced activation of PKB in PC12 cells. Similar results were obtained in cultures of chicken spinal cord motoneurons treated with brain-derived neurotrophic factor (BDNF). Moreover, CaM inhibition prevented the cell survival triggered by NGF or BDNF. This effect was counteracted by the transient expression of constitutive active forms of the PKB, indicating that CaM regulates NT-induced cell survival through the activation of the PKB. We have investigated the mechanisms whereby CaM regulates the activation of the PKB, and we have found that CaM was necessary for the proper generation and/or accumulation of the products of the PI 3-kinase in intact cells. FAU - Egea, J AU - Egea J AD - Grup de Neurobiologia Molecular, Departament de Ciencies Mediques Basiques, Facultat de Medicina, Universitat de Lleida, 25198 Lleida, Catalonia, Spain. FAU - Espinet, C AU - Espinet C FAU - Soler, R M AU - Soler RM FAU - Dolcet, X AU - Dolcet X FAU - Yuste, V J AU - Yuste VJ FAU - Encinas, M AU - Encinas M FAU - Iglesias, M AU - Iglesias M FAU - Rocamora, N AU - Rocamora N FAU - Comella, J X AU - Comella JX LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Cell Biol JT - The Journal of cell biology JID - 0375356 RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Calmodulin) RN - 0 (Chelating Agents) RN - 0 (Chromones) RN - 0 (Enzyme Inhibitors) RN - 0 (Indicators and Reagents) RN - 0 (Luminescent Proteins) RN - 0 (Morpholines) RN - 0 (Proto-Oncogene Proteins) RN - 0 (Recombinant Proteins) RN - 0 (Sulfonamides) RN - 147336-22-9 (Green Fluorescent Proteins) RN - 31M2U1DVID (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one) RN - 526U7A2651 (Egtazic Acid) RN - 81705-04-6 (N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide) RN - 9061-61-4 (Nerve Growth Factor) RN - EC 2.7.11.1 (Protein Serine-Threonine Kinases) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.11.17 (Calcium-Calmodulin-Dependent Protein Kinases) RN - K22DDW77C0 (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid) RN - SY7Q814VUP (Calcium) SB - IM MH - Animals MH - Brain-Derived Neurotrophic Factor/*pharmacology MH - Calcium/metabolism MH - Calcium-Calmodulin-Dependent Protein Kinases/metabolism MH - Calmodulin/antagonists & inhibitors/*metabolism MH - Cell Membrane/metabolism MH - Cell Survival/drug effects/physiology MH - Chelating Agents/pharmacology MH - Chromones/pharmacology MH - Egtazic Acid/analogs & derivatives/pharmacology MH - Enzyme Inhibitors/pharmacology MH - Green Fluorescent Proteins MH - Indicators and Reagents/metabolism MH - Luminescent Proteins/genetics MH - Morpholines/pharmacology MH - Nerve Growth Factor/*pharmacology MH - Neurons/*cytology/*enzymology MH - PC12 Cells MH - Phosphatidylinositol 3-Kinases/metabolism MH - Phosphorylation MH - *Protein Serine-Threonine Kinases MH - Proto-Oncogene Proteins/genetics/metabolism MH - Proto-Oncogene Proteins c-akt MH - Rats MH - Recombinant Proteins/metabolism MH - Signal Transduction/physiology MH - Sulfonamides/pharmacology PMC - PMC2196427 EDAT- 2001/08/08 10:00 MHDA- 2001/09/08 10:01 PMCR- 2002/02/06 CRDT- 2001/08/08 10:00 PHST- 2001/08/08 10:00 [pubmed] PHST- 2001/09/08 10:01 [medline] PHST- 2001/08/08 10:00 [entrez] PHST- 2002/02/06 00:00 [pmc-release] AID - 154/3/585 [pii] AID - 0101023 [pii] AID - 10.1083/jcb.200101023 [doi] PST - ppublish SO - J Cell Biol. 2001 Aug 6;154(3):585-97. doi: 10.1083/jcb.200101023.